Report Overview:
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under the skin.
This report provides a deep insight into the global Neuroblastoma Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Neuroblastoma Drugs market size was valued at US$ 1.28 billion in 2024 and is projected to reach US$ 1.89 billion by 2030, at a CAGR of 6.7% during the forecast period 2024-2030.
United States Neuroblastoma Drugs market size was valued at US$ 418.6 million in 2024 and is projected to US$ 598.4 million by 2030, at a CAGR of 6.1% during the forecast period 2024-2030. CAGR of 6.7% (2022 – 2029)
By Types:
Chemotherapy
Immunotherapy
By Applications: Hospitals
Clinics
Others
Key players include:
•Pfizer
•Teva Pharmaceutical
•Johnson & Johnson
•Bristol-Myers Squibb
•United Therapeutics
•Including or Excluding key companies relevant to your analysis.
